MedTrace Logo

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

NCT03973840 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-07-09

No results posted yet for this study

Summary

To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation

Conditions

  • Hypogonadism, Male

Interventions

DRUG

Testosterone Undecanoate

dose was given orally and allowed to reach steady state

Sponsors & Collaborators

  • Celerion; Syneos Health; ARUP Laboratories

    collaborator UNKNOWN

  • Clarus Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-15
Primary Completion
2018-07-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973840 on ClinicalTrials.gov